NO20062090L - Polymorf form av N-[(R)-2,3-dihydroksy-propksy]-3,4-difluor-2-(2-fluor-4-iodfenylamino)-benzamid - Google Patents

Polymorf form av N-[(R)-2,3-dihydroksy-propksy]-3,4-difluor-2-(2-fluor-4-iodfenylamino)-benzamid

Info

Publication number: NO20062090L
Authority: NO; Norway
Prior art keywords: polymorphic form; benzamide; difluoro; dihydroxy; propoxy
Prior art date: 2003-10-21

Application number

NO20062090A

Other languages

English (en)

Norwegian (no)

Inventor

Dainius Mackikenas

Thomas Nanninga

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-21

Filing date

2006-05-09

Publication date

2006-07-12

2006-05-09 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2006-07-12 Publication of NO20062090L publication Critical patent/NO20062090L/no

Links

SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 title abstract 2
238000002360 preparation method Methods 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton

NO20062090A 2003-10-21 2006-05-09 Polymorf form av N-[(R)-2,3-dihydroksy-propksy]-3,4-difluor-2-(2-fluor-4-iodfenylamino)-benzamid NO20062090L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US51298003P	2003-10-21	2003-10-21
PCT/IB2004/003309 WO2005040098A1 (en)	2003-10-21	2004-10-11	Polymorphic form of n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide

Publications (1)

Publication Number	Publication Date
NO20062090L true NO20062090L (no)	2006-07-12

Family

ID=34520067

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20062090A NO20062090L (no)	2003-10-21	2006-05-09	Polymorf form av N-[(R)-2,3-dihydroksy-propksy]-3,4-difluor-2-(2-fluor-4-iodfenylamino)-benzamid

Country Status (19)

Country	Link
US (1)	US7060856B2 (zh)
EP (1)	EP1682495A1 (zh)
JP (1)	JP2007509125A (zh)
KR (1)	KR101013932B1 (zh)
CN (1)	CN100594212C (zh)
AR (1)	AR046124A1 (zh)
AU (1)	AU2004283148A1 (zh)
BR (1)	BRPI0415710A (zh)
CA (1)	CA2542210A1 (zh)
CO (1)	CO5690569A2 (zh)
HK (1)	HK1093483A1 (zh)
IL (1)	IL174367A0 (zh)
MX (1)	MXPA06004363A (zh)
NO (1)	NO20062090L (zh)
NZ (1)	NZ546011A (zh)
RU (1)	RU2352558C2 (zh)
TW (1)	TW200524584A (zh)
WO (1)	WO2005040098A1 (zh)
ZA (1)	ZA200602250B (zh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2292721T3 (es) *	2001-03-27	2008-03-16	Dainippon Sumitomo Pharma Co., Ltd.	Derivado de isoxazol cristalino y preparacion medica del mismo.
WO2006061712A2 (en) *	2004-12-10	2006-06-15	Pfizer Inc.	Use of mek inhibitors in treating abnormal cell growth
WO2006134469A1 (en) *	2005-06-14	2006-12-21	Warner-Lambert Company Llc	Methods of preparing mek inhibitor
WO2007042885A2 (en) *	2005-10-07	2007-04-19	Pfizer Products Inc.	Therapeutic combination comprising methotrexate and a specified inhibitor of mek1 and mek2
US8986253B2 (en)	2008-01-25	2015-03-24	Tandem Diabetes Care, Inc.	Two chamber pumps and related methods
US8408421B2 (en)	2008-09-16	2013-04-02	Tandem Diabetes Care, Inc.	Flow regulating stopcocks and related methods
US8650937B2 (en)	2008-09-19	2014-02-18	Tandem Diabetes Care, Inc.	Solute concentration measurement device and related methods
CA2753214C (en)	2009-02-27	2017-07-25	Tandem Diabetes Care, Inc.	Methods and devices for determination of flow reservoir volume
US9250106B2 (en)	2009-02-27	2016-02-02	Tandem Diabetes Care, Inc.	Methods and devices for determination of flow reservoir volume
CA2769030C (en)	2009-07-30	2016-05-10	Tandem Diabetes Care, Inc.	Infusion pump system with disposable cartridge having pressure venting and pressure feedback
SG10201405568UA (en)	2009-09-08	2014-11-27	Hoffmann La Roche	4-substituted pyridin-3-yl-carboxamide compounds and methods of use
WO2011080510A1 (en)	2009-12-31	2011-07-07	Centro Nacional De Investigaciones Oncológicas (Cnio)	Tricyclic compounds for use as kinase inhibitors
EP2526102B1 (en)	2010-01-22	2017-03-08	Fundación Centro Nacional de Investigaciones Oncológicas Carlos III	Inhibitors of PI3 kinase
EP2536720A1 (en)	2010-02-18	2012-12-26	Centro Nacional de Investigaciones Oncológicas (CNIO)	Triazolo [4, 5 - b]pyridin derivatives
WO2011121317A1 (en)	2010-04-01	2011-10-06	Centro Nacional De Investigaciones Oncologicas (Cnio)	Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
WO2012052745A1 (en)	2010-10-21	2012-04-26	Centro Nacional De Investigaciones Oncológicas (Cnio)	Combinations of pi3k inhibitors with a second anti -tumor agent
WO2012098387A1 (en)	2011-01-18	2012-07-26	Centro Nacional De Investigaciones Oncológicas (Cnio)	6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
CN102649773A (zh) *	2011-02-23	2012-08-29	苏州波锐生物医药科技有限公司	氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途
EP2694073B1 (en)	2011-04-01	2018-08-08	Genentech, Inc.	Combinations of akt and mek inhibitors for treating cancer
RS56759B1 (sr)	2011-04-01	2018-04-30	Genentech Inc	Kombinacija akt inhibitor jedinjenja i abiraterona za upotrebu pri terapeutskim tretiranjima
CN103748099B (zh)	2011-05-19	2016-08-17	卡洛斯三世国家癌症研究中心基金会	作为蛋白激酶抑制剂的大环化合物
EP2524918A1 (en)	2011-05-19	2012-11-21	Centro Nacional de Investigaciones Oncológicas (CNIO)	Imidazopyrazines derivates as kinase inhibitors
WO2013005041A1 (en)	2011-07-07	2013-01-10	Centro Nacional De Investigaciones Oncológicas (Cnio)	Tricyclic heterocyclic compounds as kinase inhibitors
WO2013005057A1 (en)	2011-07-07	2013-01-10	Centro Nacional De Investigaciones Oncológicas (Cnio)	New compounds
WO2013004984A1 (en)	2011-07-07	2013-01-10	Centro Nacional De Investigaciones Oncologicas (Cnio)	Tricyclic compounds for use as kinase inhibitors
US9180242B2 (en)	2012-05-17	2015-11-10	Tandem Diabetes Care, Inc.	Methods and devices for multiple fluid transfer
US9555186B2 (en)	2012-06-05	2017-01-31	Tandem Diabetes Care, Inc.	Infusion pump system with disposable cartridge having pressure venting and pressure feedback
CN103570594A (zh) *	2012-08-01	2014-02-12	苏州迈泰生物技术有限公司	二芳基胺类化合物及其在制备抗恶性肿瘤药物中的用途
US9173998B2 (en)	2013-03-14	2015-11-03	Tandem Diabetes Care, Inc.	System and method for detecting occlusions in an infusion pump
US11084780B1 (en)	2021-02-17	2021-08-10	Springworks Therapeutics, Inc.	Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
CA3207513A1 (en)	2021-02-17	2022-08-25	Kristin Patterson	Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and uses thereof
AU2021428601A1 (en)	2021-02-17	2023-09-28	Springworks Therapeutics, Inc.	Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4- difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
IL304974A (en)	2021-02-17	2023-10-01	Warner Lambert Co	Preparations of mainly pure configuration IV of N-((R)-3,2-dihydroxypropoxy)-4,3-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and their uses
US11571402B2 (en)	2021-02-17	2023-02-07	Springworks Therapeutics, Inc.	Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11066358B1 (en)	2021-02-17	2021-07-20	Warner-Lambert Company Llc	Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11806322B2 (en)	2022-03-17	2023-11-07	Springworks Therapeutics, Inc.	Mirdametinib treatment
US11780800B1 (en)	2022-03-17	2023-10-10	Springworks Therapeutics, Inc.	Fluorinated phenylamino compounds and pharmaceutical compositions
WO2023223205A1 (en)	2022-05-17	2023-11-23	Teva Pharmaceuticals International Gmbh	Solid state forms of mirdametinib and process for preparation thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5155110A (en) *	1987-10-27	1992-10-13	Warner-Lambert Company	Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
WO1998037881A1 (en)	1997-02-28	1998-09-03	Warner Lambert Company	Method of treating or preventing septic shock by administering a mek inhibitor
WO1999001421A1 (en)	1997-07-01	1999-01-14	Warner-Lambert Company	2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
EP0993439B1 (en)	1997-07-01	2004-09-29	Warner-Lambert Company LLC	4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
GB9726851D0 (en) *	1997-12-19	1998-02-18	Zeneca Ltd	Human signal transduction serine/threonine kinase
US6150401A (en)	1998-01-06	2000-11-21	The General Hospital Corporation	Use of MEK1 inhibitors as protective agents against damage due to ischemia
EP1133467B1 (en)	1998-12-04	2004-09-15	Neurosearch A/S	Ion channel modulating agents
CA2346684A1 (en)	1998-12-15	2000-06-22	Warner-Lambert Company	Use of a mek inhibitor for preventing transplant rejection
CA2346448A1 (en)	1998-12-16	2000-06-22	Warner-Lambert Company	Treatment of arthritis with mek inhibitors
EE200100339A (et)	1998-12-22	2002-10-15	Warner-Lambert Company	Kombineeritud kemoteraapia
WO2000040235A2 (en)	1999-01-07	2000-07-13	Warner-Lambert Company	Treatment of asthma with mek inhibitors
EP1140067A1 (en)	1999-01-07	2001-10-10	Warner-Lambert Company	Antiviral method using mek inhibitors
AU2482800A (en)	1999-01-13	2000-08-01	Warner-Lambert Company	Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
JP2001055376A (ja)	1999-01-13	2001-02-27	Warner Lambert Co	ジアリールアミン
WO2000041505A2 (en)	1999-01-13	2000-07-20	Warner-Lambert Company	Anthranilic acid derivatives
CA2355470C (en) *	1999-01-13	2008-09-30	Warner-Lambert Company	Benzoheterocycles and their use as mek inhibitors
ATE309205T1 (de)	1999-01-13	2005-11-15	Warner Lambert Co	Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren
CA2348236A1 (en)	1999-01-13	2000-07-20	Stephen Douglas Barrett	4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
NZ513432A (en)	1999-01-13	2004-02-27	Warner Lambert Co	1-heterocycle substituted diarylamines
PL352705A1 (en)	1999-07-16	2003-09-08	Warner-Lambert Company	Method for treating chronic pain using mek inhibitors
JP2003504400A (ja)	1999-07-16	2003-02-04	ワーナー−ランバート・カンパニー	Ｍｅｋ阻害剤を用いた慢性痛の治療方法
DK1202724T3 (da)	1999-07-16	2004-01-26	Warner Lambert Co	Fremgangsmåde til behandling af kronisk smerte under anvendelse af mek-inhibitorer
ES2335265T3 (es)	1999-12-28	2010-03-24	Pharmacopeia, Inc.	Inhibidores de citoquina, especialmente de tnf-alfa.
JP2003527379A (ja)	2000-03-15	2003-09-16	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	Ｍｅｘ阻害物質としての５−アミド置換ジアリールアミン類
DE10017480A1 (de) *	2000-04-07	2001-10-11	Transmit Technologietransfer	Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
DZ3401A1 (fr) *	2000-07-19	2002-01-24	Warner Lambert Co	Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
EA200300187A1 (ru)	2000-08-25	2003-08-28	УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл Эл Си	Способ получения n-арилантраниловых кислот и их производных
HUP0302928A3 (en) *	2000-09-08	2005-03-29	Ono Pharmaceutical Co	Novel crystals of n-hydroxy-2(s)-methyl-5-ethoxymethoxy-4(s)-[n-(4-phenoxyphenyl-carbonyl)amino] pentanamide, process for their production and medicines containing the crystals as the active ingredient
ATE345788T1 (de)	2001-03-06	2006-12-15	Dorian Bevec	Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber
EP1377312A4 (en)	2001-03-22	2004-10-06	Andel Inst Van	ANTHRAX LETAL FACTOR INHIBITS TUMOR GROWTH AND ANGIOGENESIS
IL149462A0 (en) *	2001-05-09	2002-11-10	Warner Lambert Co	Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
AU2002348791A1 (en) *	2001-12-21	2003-07-09	Warner-Lambert Company Llc	Modified mek1 and mek2, crystal of a peptide: ligand: cofactor complex containing such modified mek1 or mek2, and methods of use thereof
DOP2003000556A (es)	2002-01-23	2003-10-31	Warner Lambert Co	Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
JP2005515253A (ja)	2002-01-23	2005-05-26	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	Ｎ−（４−置換フェニル）−アントラニル酸ヒドロキサメートエステル
JP2006508974A (ja) *	2002-11-15	2006-03-16	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	癌を治療するためのｍｅｋ阻害剤およびカペシタビン（ｃａｐｅｃｉｔａｂｉｎｅ）を含む併用化学療法

2004
- 2004-10-11 RU RU2006113437/04A patent/RU2352558C2/ru not_active IP Right Cessation
- 2004-10-11 MX MXPA06004363A patent/MXPA06004363A/es unknown
- 2004-10-11 KR KR1020067007613A patent/KR101013932B1/ko not_active IP Right Cessation
- 2004-10-11 WO PCT/IB2004/003309 patent/WO2005040098A1/en active Application Filing
- 2004-10-11 NZ NZ546011A patent/NZ546011A/en unknown
- 2004-10-11 JP JP2006536192A patent/JP2007509125A/ja active Pending
- 2004-10-11 CN CN200480030534A patent/CN100594212C/zh not_active Expired - Fee Related
- 2004-10-11 AU AU2004283148A patent/AU2004283148A1/en not_active Abandoned
- 2004-10-11 BR BRPI0415710-9A patent/BRPI0415710A/pt not_active IP Right Cessation
- 2004-10-11 CA CA002542210A patent/CA2542210A1/en not_active Abandoned
- 2004-10-11 EP EP04769603A patent/EP1682495A1/en not_active Withdrawn
- 2004-10-19 AR ARP040103782A patent/AR046124A1/es not_active Application Discontinuation
- 2004-10-20 TW TW093131810A patent/TW200524584A/zh unknown
- 2004-10-20 US US10/969,681 patent/US7060856B2/en not_active Expired - Fee Related
2006
- 2006-03-16 IL IL174367A patent/IL174367A0/en unknown
- 2006-03-17 ZA ZA200602250A patent/ZA200602250B/en unknown
- 2006-04-20 CO CO06037639A patent/CO5690569A2/es not_active Application Discontinuation
- 2006-05-09 NO NO20062090A patent/NO20062090L/no not_active Application Discontinuation
2007
- 2007-01-03 HK HK07100071.5A patent/HK1093483A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
WO2005040098A1 (en)	2005-05-06
CN1867543A (zh)	2006-11-22
HK1093483A1 (en)	2007-03-02
ZA200602250B (en)	2007-05-30
NZ546011A (en)	2009-09-25
EP1682495A1 (en)	2006-07-26
US7060856B2 (en)	2006-06-13
CN100594212C (zh)	2010-03-17
KR20060080230A (ko)	2006-07-07
BRPI0415710A (pt)	2006-12-19
MXPA06004363A (es)	2006-06-14
TW200524584A (en)	2005-08-01
RU2006113437A (ru)	2006-08-27
CA2542210A1 (en)	2005-05-06
US20050085550A1 (en)	2005-04-21
CO5690569A2 (es)	2006-10-31
KR101013932B1 (ko)	2011-02-14
AU2004283148A1 (en)	2005-05-06
RU2352558C2 (ru)	2009-04-20
IL174367A0 (en)	2006-08-01
JP2007509125A (ja)	2007-04-12
AR046124A1 (es)	2005-11-23

Legal Events

Date	Code	Title	Description
2009-05-25	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20062090L (no)	2006-07-12	Polymorf form av N-[(R)-2,3-dihydroksy-propksy]-3,4-difluor-2-(2-fluor-4-iodfenylamino)-benzamid
NO20045065L (no)	2005-01-07	Nytt formatsalt av o-desmetyl-venlafaxin
NO20053846L (no)	2005-08-16	Fremgangsmate for a modifisere legemiddel-krystalldannelse
RS50534B (sr)	2010-05-07	Intranazalna formulacija rotigotina
TW200716520A (en)	2007-05-01	3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
IL160075A0 (en)	2004-06-20	Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs
DE60204674D1 (de)	2005-07-21	Retinoid x rezeptormodulatoren
BRPI0410959A (pt)	2006-07-04	composição farmacêutica contendo inibidor de histona desacetilase
PT1445252E (pt)	2006-07-31	Derivados de sulfonamida, a sua preparacao e aplicacao co medicamentos
EA200601269A1 (ru)	2007-02-27	Лекарственное средство, содержащее производные фенилпиперазина
IL192233A0 (en)	2008-12-29	Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a subsituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing them
NO20045486L (no)	2005-02-02	Nye forbindelser og deres anvendelse
NO20052698L (no)	2005-06-06	4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gasatrintestinale lidelser.
NO20063308L (no)	2006-09-12	Kombinasjon av flupirtin og tramadol
WO2004098516A3 (en)	2005-07-07	Cyclic derivatives as modulators of chemokine receptor activity
SE0101322D0 (sv)	2001-04-12	Novel compounds
ATE547400T1 (de)	2012-03-15	N-alkylierte diaminopropanderivate als modulatoren der chemokinrezeptoraktivität
RS52260B (en)	2012-10-31	N- (2-hydroxyethyl) -N-methyl-4- (quinoline-8-yl (1- (thiazol-4-ylmethyl) piperidin-4-ylidene) methyl) benzamide, a process for its production as well as its use for treatment PAIN, TENSION AND DEPRESSION
BRPI0412459A (pt)	2006-10-17	composto tendo ação anti-hcv e seu método de produção
HUP0302276A2 (hu)	2003-11-28	Bikalutamidot és tamoxifent tartalmazó gyógyszerkombináció anti-androgén és anti-ösztrogén hatás előidézésére
NO995676L (no)	1999-11-19	Isoftalamid derivat som gul polymorf
AR052161A1 (es)	2007-03-07	Derivados de n-[1-(cianometil-carbamoil)-ciclohexil]-4-(4-propil-piperazin-1-il)-benzamida
NO20050834L (no)	2005-04-15	Ny indolinforbindelse og medisinsk anvendelse derav
EA200601086A1 (ru)	2006-12-29	Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200600454A1 (ru)	2006-08-25	Новый способ синтеза периндоприла и его фармацевтически приемлемых солей